OncoLink Cancer Treatment and Resources
Link to OncoLink

High Frequency Ultrasound (HIFU)

Ultima Vez Modificado: 15 de marzo del 2006

Question

Dear OncoLink "Ask The Experts,"

I have recently heard about HIFU treatments for prostate cancer. What can you tell me about this?

Answer

Richard Whittington, MD, Associate Professor of Radiation Oncology at the University of Pennsylvania School of Medicine, responds:

This technique uses focused ultrasound to heat small segments of the prostate. Hyperthermia units with similar heating effects were tried in the past and failed, but this new approach may be better.

In the US, there has only been one completed Phase I trial investigating whether or not this technique is safe. A Phase II study to evaluate the effectiveness of this treatment has not yet started. The Japanese and European reports look good, but they both excluded patients that didn't "heat well", which happens in about 5-10% of patients in most series. The studies don't score these cases as treatment failures, even though they started the procedure and the patient wasn't cured -- which in my mind is still a treatment failure. The study researchers also needed to take half of the patients back for a second procedure, but they don't count that as treatment failure either, even though the first procedure did not cure the patient.

With all of this, the median follow-up of survivors in most series is less than 18 months, which is too short to evaluate long-term control of the tumor. The HIFU company claims that this technique works best in stage T1c or T2a tumors, with poor results in T2b and T2c cancers. There are also somewhat better results with a PSA <10 as opposed to PSA >20. There did not appear to be a Gleason score effect on outcomes. The toxicity in most series is low. However, prostate cancers typically arise in the periphery of the gland, so the ultrasound has to heat to that distance without burning the tissue 1 or 2 mm further out. It may play a role in recurrences after radiation therapy or cryotherapy, but its role in primary therapy is unproven as of yet.

OncoLink I wish u knew...

Dr. Giantonio discusses the privileges bestowed on physicians in our society and the dangers of this. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS